Condition: Amyotrophic Lateral Sclerosis · Sponsor: AB Science
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
This description comes directly from the study's public registry record.
Clinical Study Coordinator · +33(0)147200014 · clinical@ab-science.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| University of Southern California | Los Angeles, California, United States | Recruiting |
| University of Kentucky | Lexington, Kentucky, United States | Recruiting |
| Johns Hopkins Medicine Brain Science Institute | Baltimore, Maryland, United States | Recruiting |
| Lahey Hospital and Medical Center | Burlington, Massachusetts, United States | Recruiting |
| University of Virginia Health System | Charlottesville, Virginia, United States | Recruiting |
| University Hospital Leuven (UZ Leuven) | Leuven, Belgium | Recruiting |
| Bispebjerg Hospital | Copenhagen, Denmark | Recruiting |
| CHU de Angers | Angers, France | Recruiting |
| Groupe Hospitalier Pellegrin Tripode | Bordeaux, France | Recruiting |
| Hôpital neurologique Pierre Wertheimer | Bron, France | Recruiting |
| CHU Gabriel Montpied | Clermont-Ferrand, France | Recruiting |
+ 44 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03127267